Shares in Australian biotech Sirtex fell through the floor after disappointing results from a cancer drug trial.
The shares are trading at $17.26, down more than 55%.
Study results for the drug didn’t show a statistically significant improvement in the colorectal tumours.
However, Sirtex said the preliminary analysis showed that SIR-Spheres Y-90 did result in a statistically significant improvement in liver tumours.
The final results and analysis of the study will be submitted to the American Society of Clinical Oncology Annual Meeting in Chicago in May-June.